AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02718365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wedge resection
Description: A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
Study NCT02718365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmentectomy
Description: A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
Study NCT02588963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal clearance Protocol
Description: Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
Study NCT04293211 — intervention group
Intervention type: OTHER
Intervention: Simulation
Description: To measure the efficacy of adding a high-fidelity simulation versus low fidelity simulation to the current B-Con Course. This will be assessed by evaluation of applying tourniquets properly and packing traumatic wounds as well as retention of these skills over a period of time amongst school teachers and security personnel.
Study NCT03354065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TIME OF FEEDING
Description: Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
Study NCT03354065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TIME OF FEEDING
Description: Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
Study NCT02988115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablet
Study NCT02988115 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablet
Study NCT02861521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoe lift
Description: Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
Study NCT02861521 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham shoe modification
Study NCT02710825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathy
Description: The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality.
Study NCT02710825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: superficial palpatory agreement
Description: The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
Study NCT02990273 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Study NCT03170960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound guided prostate biopsy
Description: The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
Study NCT02588963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
Study NCT00074932 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Myozyme
Description: 20 mg/kg
Study NCT02771561 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Patent Foramen Ovale Closure
Description: Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
Study NCT01558765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation
Description: Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
Study NCT04372706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-240
Description: Engineered red cells co-expressing 4-1BBL and IL-15TP
Study NCT03170960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
Study NCT01558453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30).
Study NCT00889525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
Study NCT03260296 — intervention group
Intervention type: OTHER
Intervention: self-administered structured questionnaire
Description: Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences
Study NCT02075788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial white bread
Study NCT02075788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn based products (porridge etc.)
Study NCT02075788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Millet based products (porridge etc.)
Study NCT01465815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT01465815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: Given PO
Study NCT01465815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given PO
Study NCT01465815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01465815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo planned surgery
Study NCT01465815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06256341 — intervention group
Intervention type: OTHER
Intervention: Cell cultivation, Antigen testing
Description: day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity.~No more interventions in human except blood sampling, only basic research.
Study NCT01152034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation group therapy
Description: This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
Study NCT04500886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF is a sustained-duration form of rhG-CSF, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), similar to rhG-CSF, PEG-rhG-CSF increases the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils, resulting in dose-dependent increases in neutrophils.
Study NCT04500886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
Study NCT03795727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD ring and precontoured sectional matrix by TOR VM
Description: MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a wedge was used to secure matrix in place
Study NCT03795727 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential matrix and tofflemire retainer by Kerr
Description: Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with wedge
Study NCT02189512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: cases - blood sampling controles - blood sampling
Study NCT00572208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin group
Description: Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~1. st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~2. nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~3. rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~4. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~5. th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
Study NCT00265473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Islets of Langerhans
Description: Intraportal infusion of islets of Langerhans
Study NCT04095507 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study NCT01024296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Port Close
Description: Device for applying loop suture to close surgical site
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
Study NCT02635412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scheduled timing of delivery
Study NCT02635412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scheduled timing of delivery
Study NCT01471743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advance Recovery (R)
Study NCT01471743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus (R)
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans rectal ultrasound
Description: Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
Study NCT03908450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA of coronary de novo lesion PCB
Description: PTCA of coronary de novo lesion with drug coated balloon
Study NCT03908450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTCA of coronary de novo lesion SCB
Description: PTCA of coronary de novo lesion with drug coated balloon
Study NCT00247312 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pd-103
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate biopsy
Description: Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
Study NCT04069819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 MG Oral Tablet
Description: Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
Study NCT04069819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 20 mg tablet once daily for 6 week
Study NCT04069819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 20 mg tablet once daily for 6 week
Study NCT04069819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
Study NCT04064047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
Study NCT04208152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anle138b
Description: capsule containing excipient and anle138b
Study NCT04208152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule containing excipient
Study NCT01365780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
Study NCT01921179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GOALS (Goal-Oriented Attentional Regulation)
Description: Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
Study NCT01365026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVS: Programa de Vida Saludable
Description: Lifestyle counseling and prescription
Study NCT02255968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-788
Description: EDP-788 Capsules. All interventions are given as multiple doses.
Study NCT02255968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules. All interventions are given as multiple doses
Study NCT01648517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
Study NCT01648517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
Study NCT01597973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin and meropenem
Description: colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
Study NCT01597973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin and placebo
Description: colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
Study NCT00578266 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide,Campath IH and TBI
Description: DAY 5 TREATMENT~* 6 5 CYTOXAN 50 mg/kg WITH MESNA~* 5 CYTOXAN 50 mg/kg WITH MESNA;~* 4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~* 3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~* 2 TBI; CAMPATH; TACROLIMUS~* 1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)
Study NCT03126448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Highly Sensitive Assays
Description: Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
Study NCT01599091 — intervention group
Intervention type: OTHER
Intervention: Specimens collection
Description: Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
Study NCT01921179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EDU (Brain Health Education)
Description: Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
Study NCT00051246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother-Infant Group Psychotherapy
Description: Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
Study NCT00051246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
Study NCT01927575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard X-Ray + CT
Description: Standard of Care X-Ray Imaging + CT
Study NCT02577107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02577107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conbercept
Study NCT01150929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C. Sigma knee arthroplasty
Description: Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
Study NCT03356496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirLife 4000 cc incentive spirometry device
Description: Incentive spirometry device provides improved lung expansion and respiratory muscle strength
Study NCT03072966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device (Fitbit Charge HR® or Fitbit Alta ®)
Description: Physical activities will be monitored by wearable device.
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 1
Description: QD and/or BID dosing for 28 days
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 2
Description: QD and/or BID dosing for 28 days
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 3
Description: QD and/or BID dosing for 28 days
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 - ATS907 - Dose 4
Description: QD and/or BID dosing for 28 days
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stage 1 - Vehicle
Description: QD and/or BID dosing for 28 days
Study NCT01520116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2 - ATS907 - Dose A - to be selected based on Stage 1
Description: QD and/or BID dosing for 4 days